Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

8295	Companies
114831	Keywords
55272	Articles
62429	Press releases

Home
Companies
Biophytis

BRIEF

published on 09/30/2024 at 23:05, 1 month 20 days ago

Biophytis Reports First-Half Financial Results and Updates on Business Activities

Financial Results Biophytis Clinical Trials Obesity Treatment Partnerships
PRESS RELEASE

published on 09/30/2024 at 23:00, 1 month 20 days ago

Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities
Biophytis publishes first-half financial results and business activities update, including launch of obesity program and licensing agreement with Blanver for Latin America, with a focus on key achievements and financial highlights

Financial Results Biophytis Licensing Agreement Business Activities Obesity Program
REGULATED PRESS RELEASE

published on 09/30/2024 at 23:00, 1 month 20 days ago

Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities
Biophytis publishes first-half financial results and updates on business activities, highlighting key achievements including launch of OBA program for obesity with BIO101 and exclusive licensing agreement with Blanver for Latin America

Financial Results Biophytis Latin America BIO101 OBA Program
BRIEF

published on 07/22/2024 at 08:17, 3 months 30 days ago

Biophytis Enters Asia Market with Strategic Partnerships

Biophytis Pharmaceutical Partnerships Market Expansion Asia
PRESS RELEASE

published on 07/22/2024 at 08:12, 3 months 30 days ago

Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia
Biophytis signs partnership contracts with local agents in Asia to accelerate deployment of BIO101 drug candidate, targeting age-related diseases in key markets like Japan and China

Biophytis Partnership Asia Age-related Diseases BIO101
BRIEF

published on 07/22/2024 at 07:05, 3 months 30 days ago

Biophytis Signs Contracts with Local Agents in Asia

Biotechnology Pharmaceutical Partnerships Age-related Diseases Asia Market
REGULATED PRESS RELEASE

published on 07/22/2024 at 07:00, 3 months 30 days ago

Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia
Biophytis implements partnership strategy in Asia with new contracts to advance drug candidate BIO101 in Japan, South Korea, China, and Southeast Asia

Biophytis Asia Contracts Partnership Strategy Drug Candidate BIO101
BRIEF

published on 07/11/2024 at 08:18, 4 months 10 days ago

Biophytis Obtains IND Approval from FDA for Phase 2 Obesity Study

Biophytis FDA Approval Phase 2 Clinical Trial BIO101 Obesity Study
PRESS RELEASE

published on 07/11/2024 at 08:13, 4 months 10 days ago

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity
Biophytis receives FDA IND approval for phase 2 OBA study in obesity with BIO101 (20-hydroxyecdysone), focusing on muscle strength improvement. Study led by renowned expert Marc-André Cornier

FDA Biophytis Obesity IND Approval OBA Study
BRIEF

published on 07/11/2024 at 07:06, 4 months 10 days ago

Biophytis Receives FDA IND Approval for Phase 2 Obesity Study

Biophytis FDA Approval Phase 2 Study BIO101 Obesity

Accesswire

Published on 11/21/2024 at 10:03, 38 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 41 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 41 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 6 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 16 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:30, 11 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 36 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 38 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 41 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 41 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 43 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 21 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 56 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 56 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE